S35 Efficacy and safety of the direct switch from various previous treatments to glycopyrronium or indacaterol/glycopyrronium in patients with moderate copd: the crystal study

C Vogelmeier; M Aalamian-Mattheis; T Greulich; J M Marin; W Castellani; T Similowski; V Ninane; M Gaga; S Lane; X Nunez; F Patalano; A Clemens; K Kostikas

doi:10.1136/thoraxjnl-2016-209333.41

Article info

Beyond FEV1 in COPD

S35 Efficacy and safety of the direct switch from various previous treatments to glycopyrronium or indacaterol/glycopyrronium in patients with moderate copd: the crystal study

Authors

C Vogelmeier 1University Medical Centre Giessen and Marburg, Marburg, Germany PubMed articles Google scholar articles
M Aalamian-Mattheis 2Novartis Pharma AG, Basel, Switzerland PubMed articles Google scholar articles
T Greulich 1University Medical Centre Giessen and Marburg, Marburg, Germany PubMed articles Google scholar articles
J M Marin 3Respiratory Medicine, Hospital Universitario Miguel Servet, Zaragoza, Spain PubMed articles Google scholar articles
W Castellani 4Department of Respiratory Physiopathology, Palagi Hospital, Florence, Italy PubMed articles Google scholar articles
T Similowski 5Respiratory Medicine and Intensive Care, Pitié – Salpêtrière Hospital, Paris, France PubMed articles Google scholar articles
V Ninane 6CHU Saint-Pierre – Service de Pneumologie, Brussells, Belgium PubMed articles Google scholar articles
M Gaga 7Athens Chest Hospital “Sotiria”, Athens, Greece PubMed articles Google scholar articles
S Lane 8Adelaide and Meath Hospital, Dublin, Ireland PubMed articles Google scholar articles
X Nunez 9TFS Develop, Barcelona, Spain PubMed articles Google scholar articles
F Patalano 2Novartis Pharma AG, Basel, Switzerland PubMed articles Google scholar articles
A Clemens 2Novartis Pharma AG, Basel, Switzerland PubMed articles Google scholar articles
K Kostikas 2Novartis Pharma AG, Basel, Switzerland PubMed articles Google scholar articles

Citation

Vogelmeier C, Aalamian-Mattheis M, Greulich T, et al

S35 Efficacy and safety of the direct switch from various previous treatments to glycopyrronium or indacaterol/glycopyrronium in patients with moderate copd: the crystal study

Thorax 2016;71:A22.

Publication history

First published November 15, 2016.

Online issue publication

September 01, 2022

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Main menu

Authors

Citation

Publication history

Request permissions

Copyright information

Log in using your username and password

Main menu

Log in using your username and password

You are here

Authors

Citation

Publication history

Request permissions

Copyright information

Read the full text or download the PDF:

Log in using your username and password